Eurofarma
Pavel Herman currently serves as Director of Eurofarma Ventures, responsible for managing Eurofarma's corporate venture fund with a focus on early-stage biotech investments primarily in the US and Europe. With extensive experience in mergers and acquisitions, Pavel has completed over 25 transactions valued at approximately US$ 750 million while previously holding roles as Executive Manager of M&A at Eurofarma, Manager of Corporate Finance at KPMG, and M&A Analyst at Walmart. Educational credentials include a dual Bachelor's and Master's degree in Electronics & Telecommunications Engineering and Economics & Management in Industry from the Czech Technical University in Prague, as well as recent completion of a Venture Capital course at GoingVC and an exchange program in Mandarin Chinese at Chung Hua University in Taiwan.
This person is not in any teams
Eurofarma
5 followers
Since its establishment in 1972, Eurofarma has been operating in the health industry, producing and marketing products and services to improve people's quality of life. Focused on generating shared value, it operates in the areas of Prescription, Nos-Prescription, Generics, Hospital and Oncology. It offers over 700 products, over 2,000 SKUs and serves 42 medical specialties. In Brazil, it covers 100 therapeutic classes, which represent 70% of prescriptions in the entire market. Operating in 20 countries, with manufacturing facilities in Brazil and industrial parks in six other Latin American countries, it generated net sales of R$ 7.1 billion in 2021, a growth of 23% compared to the previous year, and employs more than 8,100 people.